Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Preferred Stock Liabilities (2024)

Avalo Therapeutics (AVTX) has disclosed Preferred Stock Liabilities for 3 consecutive years, with $1.7 million as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Preferred Stock Liabilities changed N/A year-over-year to $1.7 million, compared with a TTM value of $1.7 million through Sep 2024, changed N/A, and an annual FY2014 reading of $28.3 million, changed N/A over the prior year.
  • Preferred Stock Liabilities was $1.7 million for Q3 2024 at Avalo Therapeutics, down from $11.5 million in the prior quarter.
  • Across five years, Preferred Stock Liabilities topped out at $11.5 million in Q1 2024 and bottomed at $1.7 million in Q3 2024.